Genomes and Genes
V H Shah
Affiliation: Mayo Clinic
- Gene transfer of recombinant endothelial nitric oxide synthase to liver in vivo and in vitroV Shah
Gastrointestinal Research Unit and Anesthesia Research Unit, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Physiol Gastrointest Liver Physiol 279:G1023-30. 2000..These events were associated with increased ionomycin-stimulated NO release. In summary, this is the first study to demonstrate successful delivery of the recombinant eNOS gene to liver in vivo and in vitro with ensuing NO production...
- Molecular mechanisms of increased intrahepatic resistance in portal hypertensionVijay Shah
Gastrointestinal Research Unit and Advanced Liver Disease Study Group, Mayo Clinic, Rochester, MN, USA
J Clin Gastroenterol 41:S259-61. 2007..This review will focus on these processes within the intrahepatic circulation, a circulatory bed whose study, that Dr Roberto Groszmann has pioneered...
- Nitric oxide in gastrointestinal health and diseaseVijay Shah
GI Research Unit, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Gastroenterology 126:903-13. 2004....
- Mechanisms of nitric oxide interplay with Rho GTPase family members in modulation of actin membrane dynamics in pericytes and fibroblastsJune Sung Lee
GI Research Unit, Al 2 435, Mayo Clinic, 200 First St SW, Rochester, MN 55905
Am J Pathol 166:1861-70. 2005..In conclusion, these studies identify novel crosstalk between small GTPases, cytoskeletal structures, and NO in pericyte-specific pathways, providing counterbalances in the chemotactic responses to growth factors...
- Management of portal hypertensionVijay H Shah
Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Postgrad Med 119:14-8. 2006..Because the prognosis for patients with hepatic encephalopathy is generally poor, orthotopic liver transplantation should be considered...
- Nitric oxide in liver transplantation: pathobiology and clinical implicationsVijay Shah
GI Research Unit and Advanced Liver Disease Study Group, Department of Medicine, Alfred 2 435, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Liver Transpl 9:1-11. 2003..This review article focuses on new advances relating to the role of nitric oxide in these syndromes with an emphasis on pathobiology and potential clinical implications...
- Cellular and molecular basis of portal hypertensionV Shah
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
Clin Liver Dis 5:629-44. 2001....
- Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in ratsV Shah
Gastrointestinal Research Unit, Mayo Clinic, Rochester, MN 55905, USA
Am J Physiol Gastrointest Liver Physiol 280:G1209-16. 2001..We conclude that, in cholestatic portal hypertension, caveolin may negatively regulate NOS activity in a manner that is reversible by excess calmodulin...
- Vascular biology and pathobiology of the liver: Report of a single-topic symposiumYasuko Iwakiri
Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
Hepatology 47:1754-63. 2008..Finally, clinical and translational sessions focused on emerging therapies and technologies to treat vascular diseases of the liver...
- Focal adhesion assembly in myofibroblasts fosters a microenvironment that promotes tumor growthNingling Kang
Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Pathol 177:1888-900. 2010..Taken together, our results identify Ena/VASP as a significant modifier of tumor growth through regulation of FA dynamics and ensuing pericyte/myofibroblast function within the tumor microenvironment...
- KLF11-mediated repression antagonizes Sp1/sterol-responsive element-binding protein-induced transcriptional activation of caveolin-1 in response to cholesterol signalingSheng Cao
Gastroenterology Research Unit and Tumor Biology Program, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
J Biol Chem 280:1901-10. 2005....
- Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and functionDavid Semela
GI Research Unit Fitterman Center for Digestive Disease, Mayo Clinic, Rochester, Minnesota, USA
Gastroenterology 135:671-9. 2008....
- Inhibition of GTP-dependent vesicle trafficking impairs internalization of plasmalemmal eNOS and cellular nitric oxide productionSuvro Chatterjee
GI Research Unit, Department of Physiology, and Tumor Biology Program, Mayo Clinic, Rochester, MN 55905, USA
J Cell Sci 116:3645-55. 2003....
- Centrilobular necrosis after orthotopic liver transplantation: association with acute cellular rejection and impact on outcomeZiad Hassoun
Advanced Liver Disease Study Group, Mayo Clinic, Rochester, MN, USA
Liver Transpl 10:480-7. 2004..In conclusion, the presence of cholestasis and lobular inflammation on biopsies with CN appeared helpful in predicting its association with ACR...
- Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signalingResham Bhattacharya
Department of Biochemistry and Molecular Biology, Mayo Clinic Cancer Center, Rochester, Minnesota 55905, USA
FASEB J 19:1692-4. 2005..Taken together, our findings suggest that dynamin-2 regulates KDR expression and function and hence plays an important role in VPF/VEGF mediated angiogenesis...
- Characterization of the CXCR4 signaling in pancreatic cancer cellsDaniel D Billadeau
Oncology Research Department, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Int J Gastrointest Cancer 37:110-9. 2006....
- Inhibition of VEGF- and NO-dependent angiogenesis does not impair liver regenerationU Shergill
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Am J Physiol Regul Integr Comp Physiol 298:R1279-87. 2010..In summary, inhibition of VEGF- and NO-dependent angiogenesis does not impair liver regeneration, indicating signaling redundancies that allow liver regeneration to continue in the absence of this canonical vascular pathway...
- Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2Ningling Kang Decker
GI Research Unit, Department of Physiology and Tumor Biology Program, Mayo Clinic, Rochester, MN 55903, USA
J Cell Sci 120:492-501. 2007....
- Serotonin transporter polymorphisms in patients with portopulmonary hypertensionKari E Roberts
Department of Medicine, Tufts Medical Center, Boston, MA, USA
Chest 135:1470-5. 2009..We hypothesized that the long allele or other polymorphisms in SERT would be associated with an increased risk of portopulmonary hypertension (PPHTN) in patients with advanced liver disease...
- Diverse origin and function of cells with endothelial phenotype obtained from adult human bloodRajiv Gulati
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, 200 First St SW, Rochester, Minn 55905, USA
Circ Res 93:1023-5. 2003....
- The proline-rich domain of dynamin-2 is responsible for dynamin-dependent in vitro potentiation of endothelial nitric-oxide synthase activity via selective effects on reductase domain functionSheng Cao
Gastrointestinal Research Unit and Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
J Biol Chem 278:5894-901. 2003....
- Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitisBrianna E Vaa
Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA
Mayo Clin Proc 86:37-42. 2011....
- Genetic risk factors for portopulmonary hypertension in patients with advanced liver diseaseKari E Roberts
Department of Medicine, Tufts Medical Center, Boston, MA 02111, USA
Am J Respir Crit Care Med 179:835-42. 2009..Portopulmonary hypertension (PPHTN) occurs in 6% of liver transplant candidates. The pathogenesis of this complication of portal hypertension is poorly understood...
- Risk factors and impact of chronic obstructive pulmonary disease in candidates for liver transplantationDebbie Rybak
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
Liver Transpl 14:1357-65. 2008..Older age and smoking are significant risk factors of COPD, which has adverse consequences on functional status and quality of life in these patients...
- Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver diseaseKari E Roberts
Department of Medicine, Tufts Medical Center, Boston, Massachusetts 02111, USA
Gastroenterology 139:130-9.e24. 2010..We investigated genetic risk factors for HPS in patients with advanced liver disease...
- Interplay of tumor microenvironment cell types with parenchymal cells in pancreatic cancer development and therapeutic implicationsPraveen Guturu
Gastroenterology Research Unit and Fiterman Center for Digestive Diseases, Mayo Clinic Rochester MN, 200 First Street SW, Rochester, MN 55905, USA
J Gastrointest Cancer 40:1-9. 2009..The process of "induction," namely, the formation of a tissue by the functional interaction between the epithelial layer and the stroma, is key for the development of many organs, in particular to the pancreas...
- The Budd-Chiari syndromeK V Narayanan Menon
Advanced Liver Disease Study Group, Division of Gastroenterology and Hepatology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
N Engl J Med 350:578-85. 2004
- Ephrin B2/EphB4 pathway in hepatic stellate cells stimulates Erk-dependent VEGF production and sinusoidal endothelial cell recruitmentAmitava Das
Gastroenterology Research Unit, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
Am J Physiol Gastrointest Liver Physiol 298:G908-15. 2010..These studies identify EphrinB2 or EphB4 as a key intermediary that links HSC signal transduction pathways with angiogenesis and sinusoidal remodeling...
- Leptin induces phagocytosis of apoptotic bodies by hepatic stellate cells via a Rho guanosine triphosphatase-dependent mechanismJoy X Jiang
Department of Internal Medicine, Division of Gastroenterology and Hepatology, UC Davis Medical Center, Sacramento, CA 95817, USA
Hepatology 48:1497-505. 2008..Leptin-mediated phagocytic activity of stellate cells therefore could be an important mechanism responsible for progression of fibrosis in non-alcoholic steatohepatitis...
- Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidatesMichael B Fallon
Department of Medicine, University of Alabama, Birmingham, Alabama 35294 0005, USA
Gastroenterology 135:1168-75. 2008..We assessed the impact of HPS in patients evaluated for liver transplantation...
- Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migrationAmitava Das
Gastroenterology Research Unit, Department of Physiology and Cancer Cell Biology Program, Mayo Clinic, Rochester, Minnesota 55905, USA
J Biol Chem 281:39105-13. 2006..Thus, together, these studies identify a mechanism for antagonizing Sp/KLF protein repression function via SHP, with this process regulating endothelial cell motility...
- Nitric oxide regulates tumor cell cross-talk with stromal cells in the tumor microenvironment of the liverNingling Kang Decker
Department of Physiology, Mayo Clinic Rochester, MN 55905, USA
Am J Pathol 173:1002-12. 2008..Thus, a NO gradient within the tumor microenvironment influences tumor progression through orchestrated molecular interactions between tumor cells and stroma...
- Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesisDaniel A Langer
Gastroenterology Research Unit, Department of Physiology and Tumor Biology Program, Al 2-435, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
J Hepatol 44:209-16. 2006
- Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte?June Sung Lee
Department of Internal Medicine, Inje University Ilsanpaik Hospital, Gyeonggi-do, South Korea
Hepatology 45:817-25. 2007
- Defects in cGMP-PKG pathway contribute to impaired NO-dependent responses in hepatic stellate cells upon activationRoman E Perri
Gastroenterology Research Unit, Department of Physiology, and Tumor Biology Program, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA
Am J Physiol Gastrointest Liver Physiol 290:G535-42. 2006..Activating targets downstream from NO-cGMP in activated HSC may represent a novel therapeutic target for portal hypertension...
- Carbon monoxide activates human intestinal smooth muscle L-type Ca2+ channels through a nitric oxide-dependent mechanismInja Lim
Enteric Neuroscience Program, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Am J Physiol Gastrointest Liver Physiol 288:G7-14. 2005..CO-induced NO production may explain the apparent discrepancy between the low affinity of guanylyl cyclase for CO and the robust cGMP production evoked by CO...
- Inhibition of ATP binding to the carboxyl terminus of Kir6.2 by epoxyeicosatrienoic acidsXiao Li Wang
Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Biochim Biophys Acta 1761:1041-9. 2006..These findings suggest that the epoxide group in EETs is important for modulation of ATP binding to Kir6.2. We conclude that EETs bind to the C-terminus of K(ATP) channels, inhibiting binding of ATP to the channel...
- A gas, an amino acid, and an imposter: the story of nitric oxide, L-arginine, and ADMA in portal hypertensionDaniel A Langer
Hepatology 42:1255-7. 2005
- Proteasome inhibition induces hepatic stellate cell apoptosisAkira Anan
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Hepatology 43:335-44. 2006..In conclusion, proteasome inhibition is a potential therapeutic strategy for inducing HSC apoptosis and inhibiting liver fibrogenesis...
- Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen speciesDaniel A Langer
Gastrointestinal Research Unit and Fiterman Center for Digestive Disease, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Hepatology 47:1983-93. 2008..CONCLUSION: We postulate that NO-dependent apoptosis of HSCs may maintain sinusoidal homeostasis, and may represent an additional beneficial effect of NO donors for therapy of portal hypertension...
- Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivoEugenia Trushina
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
Hum Mol Genet 15:3578-91. 2006..These data provide the first direct link between mhtt and caveolar-related endocytosis and also suggest a possible mechanism for HD neurotoxicity where cholesterol homeostasis is perturbed...
- Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein traffickingYasuko Iwakiri
Section of Digestive Diseases, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510, USA
Proc Natl Acad Sci U S A 103:19777-82. 2006..These data indicate that local NOS action generates organelle-specific protein S-nitrosylation reactions that can regulate intracellular transport processes...
- Caveolae targeting and regulation of large conductance Ca(2+)-activated K+ channels in vascular endothelial cellsXiao-Li Wang
Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
J Biol Chem 280:11656-64. 2005..These novel findings may have important implications for the role of BK channels in the regulation of endothelial function...
- MULTIDISCIPLINARY TRAINING IN DIGESTIVE DISEASESVijay Shah; Fiscal Year: 2007..This well established but dynamic training program continues to expand and exploit new training opportunities, and remains highly successful in achieving its goal of training individuals for academic careers in enteric sciences. ..
- Molecular Mechanisms of Portal HypertensionVijay Shah; Fiscal Year: 2007..abstract_text> ..
- Molecular Mechanisms of Portal HypertensionVijay Shah; Fiscal Year: 2009....
- Mechanisms of Nitric Oxide Signaling in Vascular RemodelingVijay H Shah; Fiscal Year: 2010..Thus, this work has physiologic, pathobiologic, and therapeutic importance. ..
- Molecular Mechanisms of Portal HypertensionVijay H Shah; Fiscal Year: 2010....
- Failure of FasL Mediated Pathways in Tumor AngiogenesisVijay Shah; Fiscal Year: 2006..These insights may lead to novel and effective therapeutic strategies that target this pathway to prevent angiogenesis, and thereby prevent colorectal tumor development growth and spread. ..
- Molecular Mechanisms of Portal HypertensionVijay Shah; Fiscal Year: 2006....
- Inhibition of TNF in Patients with Alcoholic HepatitisVijay Shah; Fiscal Year: 2005..abstract_text> ..
- REG OF NITRIC OXIDE PRODUCT IN THE HEPATIC CIRCULATIONVijay Shah; Fiscal Year: 2002..Defining the mechanisms that regulate nitric oxide production in SEC may lead to therapeutic options whereby NO activity may be pharmacologically or genetically modulated and benefit patients with cirrhosis and portal hypertension. ..
- Endothelial Nitric Oxide Synthase & Portal HypertensionVijay Shah; Fiscal Year: 2002..abstract_text> ..
- Molecular Mechanisms of Portal HypertensionVijay Shah; Fiscal Year: 2009....